dAurAB2

Overview

dAurAB2 is a dual-degrading PROTAC that potently degrades Aurora-A and Aurora-B with DC 50 s of 59 nM and 39 nM, respectively. dAurAB2 reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells. dAurAB2 can be used for the study of neuroblastoma. (Pink, Aurora ligand ( HY-10804 ); Blue, E3 ligand: ( HY-103597 ); Black, linker ( HY-W105740 )). (Pink: Aurora A and Aurora B ligand ( HY-10804 ); Blue: Cereblon ligand ( HY-103597 ); Black: linker ( HY-W105740 )).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Aurora Kinase

Product Information

• Catalog No.: HY-171769
• CAS No.: 3115765-38-0
• Molecular Formula: C52H62BrN11O8
• Molecular Weight: 1049.02
• Purity: 98.61%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (4.77 mM); Clear solution
• Availability: In-stock

Source

Original product source